Annual CFF
$880.00 K
-$11.99 M-93.16%
31 December 2023
Summary:
Adaptimmune Therapeutics annual cash flow from financing activities is currently $880.00 thousand, with the most recent change of -$11.99 million (-93.16%) on 31 December 2023. During the last 3 years, it has fallen by -$339.17 million (-99.74%). ADAP annual CFF is now -99.74% below its all-time high of $340.05 million, reached on 31 December 2020.ADAP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$25.00 M
+$489.00 K+1.99%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly cash flow from financing activities is currently $25.00 million, with the most recent change of +$489.00 thousand (+1.99%) on 30 September 2024. Over the past year, it has increased by +$24.41 million (+4094.80%). ADAP quarterly CFF is now -89.92% below its all-time high of $248.02 million, reached on 30 June 2020.ADAP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$78.82 M
+$24.41 M+44.85%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM cash flow from financing activities is currently $78.82 million, with the most recent change of +$24.41 million (+44.85%) on 30 September 2024. Over the past year, it has increased by +$76.61 million (+3468.22%). ADAP TTM CFF is now -76.82% below its all-time high of $340.05 million, reached on 31 December 2020.ADAP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -93.2% | +4094.8% | +3468.2% |
| 3 y3 years | -99.7% | +10000.0% | +2247.3% |
| 5 y5 years | -99.1% | +100.0% | +10000.0% |
ADAP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.7% | at low | -14.5% | >+9999.0% | at high | +8857.0% |
| 5 y | 5 years | -99.7% | +140.4% | -89.9% | -76.8% | >+9999.0% | |
| alltime | all time | -99.7% | -89.9% | +710.8% | -76.8% | +2025.7% |
Adaptimmune Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $25.00 M(+2.0%) | $78.82 M(+44.8%) |
| June 2024 | - | $24.51 M(-16.2%) | $54.42 M(+81.9%) |
| Mar 2024 | - | $29.23 M(>+9900.0%) | $29.92 M(+3299.9%) |
| Dec 2023 | $880.00 K(-93.2%) | $74.00 K(-87.6%) | $880.00 K(-60.2%) |
| Sept 2023 | - | $596.00 K(+4157.1%) | $2.21 M(-27.9%) |
| June 2023 | - | $14.00 K(-92.9%) | $3.06 M(-76.5%) |
| Mar 2023 | - | $196.00 K(-86.0%) | $13.03 M(+1.3%) |
| Dec 2022 | $12.87 M(+291.3%) | $1.40 M(-3.4%) | $12.87 M(+11.7%) |
| Sept 2022 | - | $1.45 M(-85.4%) | $11.52 M(+12.9%) |
| June 2022 | - | $9.98 M(>+9900.0%) | $10.20 M(+265.8%) |
| Mar 2022 | - | $35.00 K(-32.7%) | $2.79 M(-15.2%) |
| Dec 2021 | $3.29 M(-99.0%) | $52.00 K(-62.6%) | $3.29 M(-2.1%) |
| Sept 2021 | - | $139.00 K(-94.6%) | $3.36 M(-8.9%) |
| June 2021 | - | $2.56 M(+380.0%) | $3.69 M(-98.5%) |
| Mar 2021 | - | $534.00 K(+337.7%) | $249.14 M(-26.7%) |
| Dec 2020 | $340.05 M(>+9900.0%) | $122.00 K(-73.8%) | $340.05 M(+0.0%) |
| Sept 2020 | - | $466.00 K(-99.8%) | $339.93 M(+0.1%) |
| June 2020 | - | $248.02 M(+171.2%) | $339.46 M(+269.9%) |
| Mar 2020 | - | $91.44 M(>+9900.0%) | $91.77 M(>+9900.0%) |
| Dec 2019 | $366.00 K | $0.00(0.0%) | $366.00 K(-22.1%) |
| Sept 2019 | - | $0.00(-100.0%) | $470.00 K(-99.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $330.00 K(+816.7%) | $100.63 M(-0.6%) |
| Mar 2019 | - | $36.00 K(-65.4%) | $101.19 M(-1.5%) |
| Dec 2018 | $102.69 M(-0.8%) | $104.00 K(-99.9%) | $102.69 M(+0.1%) |
| Sept 2018 | - | $100.16 M(>+9900.0%) | $102.59 M(+3571.7%) |
| June 2018 | - | $890.00 K(-42.0%) | $2.79 M(-93.6%) |
| Mar 2018 | - | $1.53 M(>+9900.0%) | $43.70 M(-57.8%) |
| Dec 2017 | $103.57 M(>+9900.0%) | $0.00(-100.0%) | $103.57 M(-0.0%) |
| Sept 2017 | - | $370.00 K(-99.1%) | $103.58 M(+0.4%) |
| June 2017 | - | $41.80 M(-31.9%) | $103.22 M(+68.1%) |
| Mar 2017 | - | $61.40 M(>+9900.0%) | $61.41 M(>+9900.0%) |
| Dec 2016 | $17.00 K(>+9900.0%) | $17.00 K(>+9900.0%) | $17.00 K(>+9900.0%) |
| Sept 2016 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2016 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2016 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2015 | $0.00(-100.0%) | - | - |
| Sept 2015 | - | $0.00(-100.0%) | -$4.09 M(-104.3%) |
| June 2015 | $274.86 M(+1768.0%) | - | - |
| Dec 2014 | - | -$4.09 M(-104.2%) | $94.25 M(-4.2%) |
| Sept 2014 | - | $98.34 M | $98.34 M |
| June 2014 | $14.71 M(+296.8%) | - | - |
| June 2013 | $3.71 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual CFF year-on-year change?
- What is Adaptimmune Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly CFF year-on-year change?
- What is Adaptimmune Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM CFF year-on-year change?
What is Adaptimmune Therapeutics annual cash flow from financing activities?
The current annual CFF of ADAP is $880.00 K
What is the all time high annual CFF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual cash flow from financing activities is $340.05 M
What is Adaptimmune Therapeutics annual CFF year-on-year change?
Over the past year, ADAP annual cash flow from financing activities has changed by -$11.99 M (-93.16%)
What is Adaptimmune Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ADAP is $25.00 M
What is the all time high quarterly CFF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly cash flow from financing activities is $248.02 M
What is Adaptimmune Therapeutics quarterly CFF year-on-year change?
Over the past year, ADAP quarterly cash flow from financing activities has changed by +$24.41 M (+4094.80%)
What is Adaptimmune Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ADAP is $78.82 M
What is the all time high TTM CFF for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM cash flow from financing activities is $340.05 M
What is Adaptimmune Therapeutics TTM CFF year-on-year change?
Over the past year, ADAP TTM cash flow from financing activities has changed by +$76.61 M (+3468.22%)